These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11489241)

  • 1. Conflict of interest in industry-sponsored economic evaluations: real or imagined?
    Barbieri M; Drummond MF
    Curr Oncol Rep; 2001 Sep; 3(5):410-3. PubMed ID: 11489241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Industry sponsorship and research outcome.
    Lundh A; Sismondo S; Lexchin J; Busuioc OA; Bero L
    Cochrane Database Syst Rev; 2012 Dec; 12():MR000033. PubMed ID: 23235689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review.
    Jang S; Chae YK; Haddad T; Majhail NS
    Breast Cancer Res Treat; 2010 Jun; 121(2):273-9. PubMed ID: 20352486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review.
    Peura PK; Martikainen JA; Purmonen TT; Turunen JH
    Med Decis Making; 2012; 32(2):237-45. PubMed ID: 21490308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
    Friedberg M; Saffran B; Stinson TJ; Nelson W; Bennett CL
    JAMA; 1999 Oct; 282(15):1453-7. PubMed ID: 10535436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating solutions to sponsorship bias.
    Doucet M; Sismondo S
    J Med Ethics; 2008 Aug; 34(8):627-30. PubMed ID: 18667655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Industry sponsorship and authorship of clinical trials over 20 years.
    Buchkowsky SS; Jewesson PJ
    Ann Pharmacother; 2004 Apr; 38(4):579-85. PubMed ID: 14982982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between study sponsorship, risks of bias, and research outcomes in atrazine exposure studies conducted in non-human animals: Systematic review and meta-analysis.
    Bero L; Anglemyer A; Vesterinen H; Krauth D
    Environ Int; 2016; 92-93():597-604. PubMed ID: 26694022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disclosure of competing financial interests and role of sponsors in phase III cancer trials.
    Tuech JJ; Moutel G; Pessaux P; Thoma V; Schraub S; Herve C
    Eur J Cancer; 2005 Oct; 41(15):2237-40. PubMed ID: 16214044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of sponsorship bias in economic studies of antidepressants.
    Baker CB; Johnsrud MT; Crismon ML; Rosenheck RA; Woods SW
    Br J Psychiatry; 2003 Dec; 183():498-506. PubMed ID: 14645020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?
    Drummond MF
    Pharmacoeconomics; 1998 Jul; 14(1):1-9. PubMed ID: 10182189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sponsorship bias in clinical research.
    Lexchin J
    Int J Risk Saf Med; 2012; 24(4):233-42. PubMed ID: 23135338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Conflicts of interest--an evidence-based approach].
    Slørdal L; Eggen AE; Rygnestad T
    Tidsskr Nor Laegeforen; 2012 Jun; 132(11):1358-60. PubMed ID: 22717864
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted therapies: Manufacturer sponsorship bias in economic analyses matters.
    Kerr D; Elzawawy A
    Nat Rev Clin Oncol; 2012 May; 9(6):309-10. PubMed ID: 22547216
    [No Abstract]   [Full Text] [Related]  

  • 15. Industry sponsorship in research and publishing: who is really to blame for perceived bias?
    Amsden GW
    Ann Pharmacother; 2004 Apr; 38(4):714-6. PubMed ID: 14982974
    [No Abstract]   [Full Text] [Related]  

  • 16. Financial conflicts of interest and their association with outcome and quality of fibromyalgia drug therapy randomized controlled trials.
    Pang WK; Yeter KC; Torralba KD; Spencer HJ; Khan NA
    Int J Rheum Dis; 2015 Jul; 18(6):606-15. PubMed ID: 26012523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between funding by commercial interests and study outcome in randomized controlled drug trials.
    Yaphe J; Edman R; Knishkowy B; Herman J
    Fam Pract; 2001 Dec; 18(6):565-8. PubMed ID: 11739337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes.
    Nkansah N; Nguyen T; Iraninezhad H; Bero L
    Public Health Nutr; 2009 Oct; 12(10):1931-7. PubMed ID: 19254426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sources of bias in the economic analysis of new drugs. Health Outcomes Committee Pharmaceutical Research and Manufacturers of America, Washington, DC.
    Gagnon JP
    JAMA; 2000 Mar; 283(11):1423; author reply 1424. PubMed ID: 10732925
    [No Abstract]   [Full Text] [Related]  

  • 20. Modeling in pharmacoeconomic studies: funding sources and outcomes.
    Garattini L; Koleva D; Casadei G
    Int J Technol Assess Health Care; 2010 Jul; 26(3):330-3. PubMed ID: 20584363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.